JP2012526140A5 - - Google Patents

Download PDF

Info

Publication number
JP2012526140A5
JP2012526140A5 JP2012509968A JP2012509968A JP2012526140A5 JP 2012526140 A5 JP2012526140 A5 JP 2012526140A5 JP 2012509968 A JP2012509968 A JP 2012509968A JP 2012509968 A JP2012509968 A JP 2012509968A JP 2012526140 A5 JP2012526140 A5 JP 2012526140A5
Authority
JP
Japan
Prior art keywords
package
storage
less
pharmaceutical product
storage method
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2012509968A
Other languages
English (en)
Japanese (ja)
Other versions
JP5649645B2 (ja
JP2012526140A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2010/033852 external-priority patent/WO2010129757A1/en
Publication of JP2012526140A publication Critical patent/JP2012526140A/ja
Publication of JP2012526140A5 publication Critical patent/JP2012526140A5/ja
Application granted granted Critical
Publication of JP5649645B2 publication Critical patent/JP5649645B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2012509968A 2009-05-07 2010-05-06 プロスタサイクリンアナログの固形製剤 Active JP5649645B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US17626809P 2009-05-07 2009-05-07
US61/176,268 2009-05-07
PCT/US2010/033852 WO2010129757A1 (en) 2009-05-07 2010-05-06 Solid formulations of prostacyclin analogs

Publications (3)

Publication Number Publication Date
JP2012526140A JP2012526140A (ja) 2012-10-25
JP2012526140A5 true JP2012526140A5 (enExample) 2014-05-01
JP5649645B2 JP5649645B2 (ja) 2015-01-07

Family

ID=43050464

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2012509968A Active JP5649645B2 (ja) 2009-05-07 2010-05-06 プロスタサイクリンアナログの固形製剤

Country Status (7)

Country Link
US (1) US8349892B2 (enExample)
EP (1) EP2427054A4 (enExample)
JP (1) JP5649645B2 (enExample)
KR (1) KR101544246B1 (enExample)
CN (1) CN102421288B (enExample)
CA (1) CA2760499C (enExample)
WO (1) WO2010129757A1 (enExample)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2622471T5 (es) * 2003-05-22 2020-07-23 United Therapeutics Corp Compuestos y procedimientos para la administración de análogos de prostaciclina
JP2007532663A (ja) * 2004-04-12 2007-11-15 ユナイテッド セラピューティクス インコーポレイテッド ニューロパシー性の糖尿病性足潰瘍を治療するためのトレプロスチニルの使用
KR101390579B1 (ko) 2006-05-15 2014-05-19 유나이티드 세러퓨틱스 코오포레이션 정량 흡입기를 사용한 트레프로스티닐 투여
DE102006026786A1 (de) 2006-06-07 2007-12-13 Joachim Kern Dosierinhalator
CA2710205C (en) 2007-12-17 2016-04-26 United Therapeutics Corporation An improved process to prepare treprostinil, the active ingredient in remodulin
ES2611187T3 (es) 2010-03-15 2017-05-05 United Therapeutics Corporation Tratamiento para hipertensión pulmonar
CN103261142B (zh) 2010-06-03 2014-12-10 联合治疗公司 曲前列环素的制备
WO2011159693A2 (en) * 2010-06-15 2011-12-22 United Therapeutics Corporation Oral treatment of digital ischemic lesions
US20130345471A1 (en) 2011-03-02 2013-12-26 United Therapeutics Corporation Synthesis of intermediate for treprostinil production
CN103193627B (zh) 2012-01-10 2016-04-20 上海天伟生物制药有限公司 一种前列腺素类似物的晶型及其制备方法和用途
JP6542128B2 (ja) 2013-01-11 2019-07-10 コルセア ファーマ インコーポレイテッド トレプロスチニルのプロドラッグ
US9505737B2 (en) 2013-01-11 2016-11-29 Corsair Pharma, Inc. Treprostinil derivative compounds and methods of using same
CA3125504C (en) 2013-03-14 2023-10-24 United Therapeutics Corporation Solid forms of treprostinil
EP2970081A4 (en) 2013-03-15 2016-10-12 United Therapeutics Corp SALTS OF TREPROSTINIL
WO2014160638A1 (en) 2013-03-25 2014-10-02 United Therapeutics Corporation Process of making prostacyclin compounds with linker thiol and pegylated forms
SI3060041T1 (sl) 2013-10-25 2021-04-30 Insmed Incorporated Spojine prostaciklina
CA2952223C (en) 2014-06-13 2023-08-01 United Therapeutics Corporation Treprostinil formulations
WO2016064764A1 (en) 2014-10-20 2016-04-28 United Therapeutics Corporation Synthesis of intermediate for producing prostacyclin derivatives
AU2015349969B2 (en) 2014-11-18 2020-02-06 Insmed Incorporated Methods of manufacturing treprostinil and treprostinil derivative prodrugs
US9643911B2 (en) 2015-06-17 2017-05-09 Corsair Pharma, Inc. Treprostinil derivatives and compositions and uses thereof
US9394227B1 (en) 2015-06-17 2016-07-19 Corsair Pharma, Inc. Treprostinil derivatives and compositions and uses thereof
CA3038276A1 (en) 2016-09-26 2018-03-29 United Therapeutics Corporation Treprostinil prodrugs
US10799653B2 (en) 2017-01-09 2020-10-13 United Therapeutics Corporation Aerosol delivery device and method for manufacturing and operating the same
IL280891B1 (en) 2018-09-18 2025-09-01 Lilly Co Eli Treprostinil erbumine salt
CN114072136B (zh) 2019-04-29 2024-11-29 英斯梅德股份有限公司 曲前列素前药的干粉组合物及其使用方法
CN114616225A (zh) 2019-08-23 2022-06-10 联合治疗公司 曲前列环素前药
WO2021211916A1 (en) 2020-04-17 2021-10-21 United Therapeutics Corporation Treprostinil for use in the treatment of intersitial lung disease
US11793780B2 (en) 2020-06-09 2023-10-24 United Therapeutics Corporation Prodrugs of treprosiinil
WO2022132655A1 (en) 2020-12-14 2022-06-23 United Therapeutics Corporation Methods of treating disease with treprostinil prodrugs
EP4301372A1 (en) 2021-03-03 2024-01-10 United Therapeutics Corporation A dry powder composition of trestinil and its prodrug thereof and further comprising comprising (e)-3,6-bis[4-(n-carbonyl-2-propenyl)amidobutyl]-2,5-diketopiperazine (fdkp)
JP2025506019A (ja) 2022-02-08 2025-03-05 ユナイテッド セラピューティクス コーポレイション トレプロスチニルイロプロスト併用療法
KR20250002687A (ko) 2022-04-29 2025-01-07 자오커 파마슈티컬 (광저우) 컴퍼니., 리미티드 트레프로스티닐 소프트 미스트 흡입제
EP4652151A1 (en) 2023-01-19 2025-11-26 United Therapeutics Corporation Treprostinil analogs

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4306075A (en) * 1980-03-28 1981-12-15 The Upjohn Company Composition and process
GB8814438D0 (en) * 1988-06-17 1988-07-20 Wellcome Found Compounds for use in medicine
GB9011588D0 (en) * 1990-05-24 1990-07-11 Wellcome Found Prostaglandin analogues for use in medicine
US6441245B1 (en) * 1997-10-24 2002-08-27 United Therapeutics Corporation Process for stereoselective synthesis of prostacyclin derivatives
EP1045695B1 (en) * 1997-11-14 2004-03-24 United Therapeutics Corporation Use of 9-deoxy-2', 9-alpha-methano-3- oxa-4,5,6- trinor-3, 7-(1',3'-interphenylene) -13,14-dihydro- prostaglandin f 1? to treat peripheral vascular disease
US6521212B1 (en) * 1999-03-18 2003-02-18 United Therapeutics Corporation Method for treating peripheral vascular disease by administering benzindene prostaglandins by inhalation
US6700025B2 (en) * 2001-01-05 2004-03-02 United Therapeutics Corporation Process for stereoselective synthesis of prostacyclin derivatives
US6803386B2 (en) * 2002-01-16 2004-10-12 United Therapeutics Corporation Prostacyclin derivative containing compositions and methods of using the same for the treatment of cancer
EP1471049A4 (en) * 2002-01-30 2006-08-16 Kissei Pharmaceutical NEW THYROIDIAN HORMONE RECEPTOR LIGAND, MEDICINAL PREPARATIONS CONTAINING THE SAME AND USE THEREOF
ES2622471T5 (es) * 2003-05-22 2020-07-23 United Therapeutics Corp Compuestos y procedimientos para la administración de análogos de prostaciclina
US20040265238A1 (en) * 2003-06-27 2004-12-30 Imtiaz Chaudry Inhalable formulations for treating pulmonary hypertension and methods of using same
US20050101608A1 (en) * 2003-09-24 2005-05-12 Santel Donald J. Iloprost in combination therapies for the treatment of pulmonary arterial hypertension
ES2331187T3 (es) * 2003-12-16 2009-12-23 United Therapeutics Corporation Utilizacion de treprostinil para mejorar las funciones renales.
DE602004028155D1 (de) * 2003-12-16 2010-08-26 United Therapeutics Corp Verwendung von treprostinil zur behandlung von ischämischen läsionen
JP2007532663A (ja) * 2004-04-12 2007-11-15 ユナイテッド セラピューティクス インコーポレイテッド ニューロパシー性の糖尿病性足潰瘍を治療するためのトレプロスチニルの使用
ES2366375T3 (es) * 2005-02-22 2011-10-19 Pfizer, Inc. Derivados de oxiindol, como agonistas del receptor 5-ht4.
US20060222792A1 (en) * 2006-04-21 2006-10-05 Chemagis Ltd. Temozolomide storage system
US8747897B2 (en) * 2006-04-27 2014-06-10 Supernus Pharmaceuticals, Inc. Osmotic drug delivery system
KR101390579B1 (ko) * 2006-05-15 2014-05-19 유나이티드 세러퓨틱스 코오포레이션 정량 흡입기를 사용한 트레프로스티닐 투여
US20090281129A1 (en) * 2006-05-15 2009-11-12 Senex Biotechnology, Inc. Cdki pathway inhibitors and uses thereof
JP2010513533A (ja) * 2006-12-21 2010-04-30 コンサート ファーマシューティカルズ インコーポレイテッド プロスタサイクリン誘導体
US20080280986A1 (en) * 2007-02-09 2008-11-13 United Therapeutics Corporation Treprostinil treatment for interstitial lung disease and asthma
ES2560527T3 (es) * 2007-02-20 2016-02-19 Allergan Pharmaceuticals International Limited Composiciones estables de enzimas digestivas
CA2710205C (en) * 2007-12-17 2016-04-26 United Therapeutics Corporation An improved process to prepare treprostinil, the active ingredient in remodulin

Similar Documents

Publication Publication Date Title
JP2012526140A5 (enExample)
Darji et al. Excipient stability in oral solid dosage forms: a review
JP6277189B2 (ja) 苦味剤を備える水溶性パッケージ
JP5649645B2 (ja) プロスタサイクリンアナログの固形製剤
ES2669469T3 (es) Forma de dosificación farmacéutica en cápsula que comprende una formulación en suspensión de un derivado de indolinona
JP2006514119A (ja) 溶解率が向上した難溶性薬剤の溶媒系
SI2424356T1 (en) A stable pharmaceutical composition and procedures for its use
JP2014129360A5 (enExample)
CO6251277A2 (es) Inhibidor de la dpp-iv combinado con mas de un agente antidiabetico, comprimidos que comprenden tales formulaciones, su uso y procedimientos para su preparación.
CO6210803A2 (es) Formulaciones liquidas formadoras de pelicula dermica para la liberacion de farmaco a la piel
JP6533317B2 (ja) アナグリプチン含有固形製剤
JP2015505295A5 (enExample)
JP2017511816A5 (enExample)
RU2012134065A (ru) Альфа-2 адренергический агонист, обладающий эффектом длительного снижения внутриглазного давления
JP2013501780A (ja) 爪の真菌感染を治療するための組成物及び方法
CN103384518A (zh) 新的抗真菌组合物
JP2016522257A5 (enExample)
JP2008526854A5 (enExample)
JP2020510619A5 (enExample)
KR100612070B1 (ko) 용출률이 향상된 난용성 약제의 용매 시스템 및 이를 함유한 제약학적 제제
WO2011155280A1 (ja) アミノ酸含有組成物における防腐力低下抑制剤
JP6084371B2 (ja) 薬剤安定化医薬組成物
KR102384266B1 (ko) 연질 겔 캡슐에서 베타-하이드록시이소발레르산 제형의 안정화
WO2007025764A3 (de) Pharmazeutische formulierung für salze monobasischer säuren mit clopidogrel
JP2010527952A5 (enExample)